<DOC>
<DOCNO>
EP-0017355
</DOCNO>
<TEXT>
<DATE>
19801015
</DATE>
<IPC-CLASSIFICATIONS>
<main>A61K-49/02</main> G01N-33/60 A61K-51/04 A61K-51/12 A61K-51/00 A61K-51/02 
</IPC-CLASSIFICATIONS>
<TITLE>
indium-111 oxine complex composition.
</TITLE>
<APPLICANT>
amersham int plc gb  <sep>amersham international plc<sep>amersham international plcwhite lion roadamersham buckinghamshire, hp7 9llgb<sep>amersham international plc  <sep>
</APPLICANT>
<INVENTOR>
kelly james duncan<sep>kelly, james duncan<sep>kelly, james duncanc/o the radiochemical centre ltd. white lion roadamersham buckinghamshire, hp7 9llgb<sep>kelly, james duncan<sep>kelly, james duncanc/o the radiochemical centre ltd. white lion roadamersham buckinghamshire, hp7 9llgb<sep>
</INVENTOR>
<ABSTRACT>
an indium-111 preparation comprises a complex of  indium-111 with a quinoline compound carrying an 8-­ hydroxyl group, e. g.  oxine, present in an aqueous medium  which also contains a surface active agent to prevent the  complex from becoming bound to the surface of the vessel  on autoclaving, and optionally a buffer to improve blood cell  labelling efficiency.  the surface active agent is preferably  non-ionic, e. g.  a polyoxyethylene sorbitan ester of a fatty  acid.  the buffer is preferably n-2-hydroxyethylpiperazine-n′-­ 2-ethanesulphonic acid.  
</ABSTRACT>
</TEXT>
</DOC>
